88 results
DEFA14A
HARP
Harpoon Therapeutics Inc
28 Feb 24
Additional proxy soliciting materials
7:37am
targets for the Company Shares in eight publicly available Wall Street research analyst reports as of January 5, 2024 (the last trading day before … the public announcement of the Merger), which indicated low and high stock price targets for Harpoon ranging from $8.00 to $30.00 per Company Share
8-K
HARP
Harpoon Therapeutics Inc
28 Feb 24
Other Events
7:34am
targets for the Company Shares in eight publicly available Wall Street research analyst reports as of January 5, 2024 (the last trading day before … the public announcement of the Merger), which indicated low and high stock price targets for Harpoon ranging from $8.00 to $30.00 per Company Share
DEFM14A
HARP
Harpoon Therapeutics Inc
8 Feb 24
Proxy related to merger
7:00am
per Company Share.
Analyst Price Target Analysis. Centerview reviewed stock price targets for the Company Shares in publicly available Wall Street … price targets for Harpoon ranging from $8.00 to $30.00 per Company Share.
Precedent Premiums Paid Analysis. Centerview performed an analysis
PREM14A
HARP
Harpoon Therapeutics Inc
29 Jan 24
Preliminary proxy related to merger
4:52pm
Company Share.
Analyst Price Target Analysis. Centerview reviewed stock price targets for the Company Shares in publicly available Wall Street research … targets for Harpoon ranging from $8.00 to $30.00 per Company Share.
Precedent Premiums Paid Analysis. Centerview performed an analysis of premiums paid
DFAN14A
HARP
Harpoon Therapeutics Inc
8 Jan 24
Additional proxy materials by non-management
5:15pm
. Centerview Partners LLC acted as financial advisor to Harpoon and Goodwin Procter LLP acted as its legal advisor.
About HPN328
HPN328 targets delta-like
DEFA14A
hxnsqikv iqzuwh
8 Jan 24
Additional proxy soliciting materials
8:04am
8-K
EX-2.1
oidb0b
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.2
hxdt6lw
8 Jan 24
Entry into a Material Definitive Agreement
8:01am
S-8
EX-99.3
6fvkv2z6ck
5 Jan 24
Registration of securities for employees
5:04pm
8-K
EX-99.1
2fia5ocbuqslgn8x23
23 Oct 23
Other Events
8:00am
8-K
mpvwbv3zhqow775rn
13 Sep 23
Termination of a Material Definitive Agreement
4:15pm
8-K
EX-99.1
vap r9aaza
9 Aug 23
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
c8przttmh869v w40zjp
11 May 23
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
9:07pm
8-K
EX-99.2
832 rzy4qd4repa
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
ab7y ng9w
12 Dec 22
Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
4:03pm
8-K
EX-99.1
sn7cg hv0enn9v01
14 Nov 22
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
5:17pm